key: cord-0988031-s0fiiddr
authors: Zheng, Xizi; Zhao, Youlu; Yang, Li
title: Acute Kidney Injury in COVID-19: The Chinese Experience
date: 2020-09-04
journal: Semin Nephrol
DOI: 10.1016/j.semnephrol.2020.09.001
sha: d280207677760f75f763d9ad9a5100a881958c08
doc_id: 988031
cord_uid: s0fiiddr

Coronavirus disease 2019 (COVID-19) is spreading rapidly worldwide. Here, we review recently published studies on COVID-19-associated acute kidney injury (AKI) in China. The pooled incidence of AKI in all reported COVID-19 patients was 6.5%, with a much higher rate in patients from the ICU (32.5%). AKI is associated with the severity of COVID-19 and the mortality rates, which is similar to other kidney abnormalities including proteinuria and hematuria. The renal tubule is the main site of injury in COVID-19 patients, and the etiology of renal impairment in COVID-19 patients is likely diverse and multifactorial. Apart from direct viral attack via Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine proteases 2 (TMPRSS2), hypoxia and hypercoagulability may also contribute to the occurrence of renal injury. To date, there is only RCT evidence to support the use of dexamethasone in patients requiring oxygen therapy and remdesivir for shortening the time to recovery, with no specific treatment for COVID-19-associated AKI. Studies researching kidney pathologies or reporting renal outcome and prognosis are in urgent need. Further studies are urgently warranted to identify the risk factors, to predict the prognosis and renal outcome, to explore the exact mechanisms of renal injury and to suggest targeted interventions.

one of the following etiological evidence: a positive result of 2019-nCoV nucleic acid by real-time fluorescence RT-PCR or the virus gene sequence is highly homologous to the known 2019-nCoV. All confirmed cases are required to be admitted to either typical hospitals or temporary shelter hospitals according to the different degrees of disease severity. Disease severity is classified into 4 categories 4 : (1) mild: mild clinical manifestation with no unusual imaging data; (2) ordinary: fever, respiratory symptoms, pneumonia manifestation on X-ray or CT; (3) severe (satisfies any of the following): (i) respiratory distress, RR≥30 breaths/min; (ii) oxygen saturation 93% at rest state; (iii) arterial partial pressure of oxygen (PaO 2 )/inspiration O 2 (FiO 2 ) ≤300 mmHg; (4) critical (satisfies any of the following): (i) respiratory failure that needs mechanical ventilation; (ii) shock; or (iii) complicated with other organ failure that requires intensive care unit (ICU) monitoring and treatment.

To better understand the incidence of COVID-19-associated AKI in different regions of China, we selected relevant studies published until July 30, 2020, by searching PubMed using the searching terms: "coronavirus" or "COVID-19" or "SARS-CoV-2" or "2019-nCoV" and "laboratory" or "clinical". We excluded studies that had a large overlap in the enrolled patients, had less than 90 patients, or did not have a clear description of kidney function tests.

We selected relevant studies published until 26 April 2020, by searching PubMed, Web of Science, and China National Knowledge Infrastructure, using the searching terms: "coronavirus" or "COVID 19" or "SARS CoV 2" or "2019 nCoV" and "laboratory" or "clinical" and "mortality" or "outcome". Articles reporting in patients with COVID 19 on AKI and creatinine for both non survival and survival patients were included. T Observational studies from China suggest that older age 18 , hypertension 18 , cardiovascular disease 18 , COVID-19 grade 4, 21 are associated with the development of AKI in patients with . Patients with AKI are more likely to require mechanical ventilation 21 . Over 2/3 of the in-hospital AKI episodes were reported to develop after the patients reached critical illness 5 . Elevated markers of inflammation, such as ferritin, C-reactive protein, and D-dimer 4, 5 , suggest a role for inflammation in the underlying disease state. However, there are no data available on the association between medications and procedures (e.g., surgeries, contrast administration) and the development of AKI.

Similarly, male sex 41 , older age 30,41 , diabetes 41 , hypertension 41 , black race 41 , cardiovascular disease (coronary artery disease, heart failure, peripheral vascular disease) 41, 42 , respiratory disease (asthma and chronic obstructive pulmonary disease) 41 , premorbid CKD 30 , and the need for ventilator support or vasopressor drug treatment were also reported as risk factors in the USA, Italy and France. In addition, higher BMI 42 and greater baseline levels of inflammatory markers, including ferritin, CRP, procalcitonin and LDH 43 , were observed in COVID-19 patients with AKI than in non-AKI patients, which suggests the risks for developing AKI and AKI stage escalation.

The rate of AKI varies considerably among different regions and countries. Data from China suggest that AKI is less common in China than in the US, and the reported cases from China had lower rates of comorbidities such as diabetes and hypertension and a lower proportion of cases with severe respiratory disease/ARDS than the reported cases from the US 21, 41 . To date, there are no data on risk factors between different hospital settings (e.g., academic versus community, rural versus urban).

The studies of kidney involvement in COVID-19 patients reveal that abnormal urine findings, including proteinuria and hematuria, are more common than AKI 3 . In a prospective cohort study of 701 COVID-19 patients in Wuhan, 43.9% of the patients had proteinuria, 26.7% had hematuria, and 5.1% had AKI 3 . These findings were confirmed by Zheng XZ's study describing city, where the incidence of proteinuria, hematuria, and AKI was 33.5%, 21.5%, and 5.6%, respectively 5 .

As reported by Zheng XZ et al 5 , altogether 13.5% (75/555) of the patients were categorized as critical illness, and 29 patients were defined AKI (5.2%), of who 21 cases were recognized as in-hospital AKI (3.8%), and 8 (1.4%) as pre-hospital AKI. The median time of in-hospital AKI onset with respect to hospital admission was 9 (4, 13) days and to onset of COVID-19 symptoms was 18 (14, 22) days. The duration from symptom onset to critical illness and death was 13 (8, 17) days and 29 (22, 38) days, respectively( Figure 2 ). The peak stages of in-hospital AKI were stage 1 in 38% (8/21), stage 2 in 19% (4/21), and stage 3 in 43% (9/21) 5 .

In Pei GC's study 4 

To date, over 4,600 patients have died from COVID-19 in China 45 . The first postmortem tissue biopsy report of kidney pathological presentation was from 26 COVID-19 patients, and it describes extensive acute tubular injury and endothelial injury 46 . Among these 26 patients, acute tubular lesions were significant and diffuse, including the loss of brush border, vacuolar degeneration, and dilatation of the tubular lumen with cellular debris, but only 9

showed clinical signs of kidney injury, which included increased serum creatinine and/or new-onset proteinuria. Five patients presented severe pathological tubular injury with increased serum creatinine, and 2 of these patients showed multiple foci of bacteria and diffuse polymorphonuclear casts in the lumen of tubules, which was consistent with the pathological findings in the lungs. Occasional hemosiderin granules in the tubular epithelium were identified in 4 patients with hematuria using a dipstick. Another common morphologic finding was erythrocyte stagnation in the peritubular and glomerular capillary loops without distinct fragmentation of erythrocytes or platelets or fibrin thrombi. Angiotensin-converting enzyme 2 (ACE2) expression was prominent in proximal tubular cells, particularly in areas with severe acute tubular injury. Immunostaining with a SARS-CoV nucleoprotein antibody was positive in tubules, and electron microscopic examination showed clusters of coronavirus particles with distinctive spikes in the tubular epithelium and podocytes, demonstrating a direct invasion of SARS-CoV-2 into kidney tissue.

Similar results were observed in a preprint study that reported postmortem kidney biopsy findings from six COVID-19 patients with AKI 47 . Varying degrees of acute tubular necrosis, luminal brush border sloughing and vacuole degeneration were observed in all six renal specimens, and an accumulation of SARS-CoV-2 viral nucleoprotein antigen in kidney tubules was detected by immunohistochemistry. The above findings are consistent with kidney injury secondary to SARS-CoV and MERS-CoV infections, in which viral invasion was also detected in renal tubular epithelial cells 48, 49 .

The mechanism of the development of AKI in SARS-CoV-2 infection may be multifactorial and vary among cases and different disease conditions. In vitro Vero E6 and 293T cell experiments showed that the glycoprotein spikes on the outer surface of SARS-CoV are responsible for the attachment and entry of the virus into host cells 50 . Recently, another in vitro study used human kidney and airway epithelial cells and suggested that the spike protein of SARS-CoV-2 binds to ACE2 for entry and that the spike protein is activated and cleaved by cellular transmembrane serine protease 2 (TMPRSS2), allowing the virus to release fusion peptides for membrane fusion 51 . A study based on single-cell transcriptome analysis showed that the coexpression of the receptor ACE2 and TMPRSS genes in kidney cells was no less than that in the lung, esophagus, small intestine and colon, and relatively high coexpression of ACE2 and TMPRSS genes was observed in podocytes and proximal straight tubule cells 52 . These findings suggest that the kidney is an important target organ for SARS-CoV-2, with podocytes and proximal straight tubule cells as candidate host cells.

Recently, some researchers successfully isolated SARS-CoV-2 virus particles from the urine of COVID-19 patients [53] [54] [55] . Virus particles were also identified in kidney specimens of AKI patients 46, 47 . These results demonstrate that SARS-CoV-2 is a cytopathic virus that can directly infect human renal tubules and podocytes and consequently lead to AKI and proteinuria in COVID-19 patients. Clinical findings showed exuberant inflammatory responses during SARS-CoV-2 infection, further resulting in uncontrolled pulmonary inflammation, likely a leading cause of case fatality 1, 8 , suggesting that a possible cytokine storm may be involved in the occurrence and development of AKI. Other putative mechanisms include the use of renal-toxic therapies, respiratory distress syndrome-induced hypoxia, hypovolemia and hypotension.

In a large cohort of patients with end-stage kidney disease (ESKD) and undergoing maintenance hemodialysis (MHD) in Wuhan, 154 out of 7,154 patients had laboratory-confirmed COVID-19, making the incidence of COVID-19 in MHD patients 2.15%, which is much higher than that of the general population (approximately 0.5% during the same period in Wuhan) 56 . Therefore, the MHD population is highly susceptible to COVID-19, Anti-immunosuppressive therapy (e.g., calcineurin inhibitor) and rapamycin should also be reduced in moderate-severe cases. For severe patients, withdrawal of all anti-immunosuppressive therapies, except corticosteroids, is required to restore an adequate immune response.

Controlling the source and cutting off the route of transmission are the fundamental measures for the prevention and control of infectious diseases. After the outbreak of the COVID-19 epidemic, extreme disease control practices were adopted by the Chinese government to promote active case finding and case management in suppression and containment strategies.

Wuhan, the epicenter of COVID-19 in China, suspended all transportation into and out of the city from January 23 to April 8, 2020. Hospitals were required to report confirmed or suspected cases within 2 h. Laboratories reported test results within 12 h, and local Centers for Disease Control and Prevention completed case investigations within 24 h 62 . Door-to-door and individual-to-individual universal symptom surveys were initiated to single out presumptive cases in the community.

All confirmed cases were hospitalized and transferred to isolation wards in COVID-19-designated hospitals, regardless of disease severity. Presumptive cases, i.e., those with fever or respiratory symptoms, and close contacts of confirmed cases were allocated to centralized isolation sites with protective conditions. To combat the shortage of hospital beds, sixteen Fangcang shelter hospitals were rapidly built in Wuhan, which isolated more than 12,000 patients with mild and moderate COVID-19 63 . Three mobile P3 laboratories were transported to Wuhan to help enhance the capability and efficiency of nucleic acid testing 64 .

These hospitals and laboratories helped ensure that every suspected case could be tested, treated, and isolated and that their close contacts could be traced and isolated in a timely manner.

According to China's national guidelines for the prevention and control of COVID-19 62 , medical staff who provided diagnosis and treatment services to COVID-19 patients at designated medical and health institutions were required to keep effective personal protection.

Individual protective equipment, including protective clothing, medical protective masks or powered air filter respirators, and protective face screens or goggles, were necessary. All the medical staff lived in isolation, worked as a team to limit exposure to the infection, and were prohibited from working in non-COVID-19 wards during the same time. After finishing their work in the isolation wards, medical staff were also required to undergo centralized isolation 

To date, the care strategy for patients with COVID-19 and AKI is largely supportive due to the lack of specific treatments. Oxygen delivery is optimized to maintain a high level of oxygenation parameters and to prevent tissue hypoxia and worsening of AKI under severe infection 66 . Appropriate fluid management is essential, as patients with fever tend to be hypovolemia, and mechanical ventilation with high positive end expiratory pressure maneuvers might exacerbate the condition. However, avoiding volume overload and pulmonary edema are equally important 67 . The discontinuation of all potentially nephrotoxic drugs and dose adaptation of drugs excreted by the kidney are pivotal to the patient's renal function 67 . Protein-calorie malnutrition is associated with mortality in patients with AKI, and the nutritional management of AKI patients with COVID-19 is vital. In addition, there has been no evidence in recent studies showing that RAAS inhibitors would affect the risk of COVID-19 or mortality [68] [69] [70] . Therefore, cardiovascular societies recommend against the addition or cessation of RAAS inhibitors.

The use of antiviral drugs in treating COVID-19 patients varies from 21% to 94% in different studies 1-3,6,10,71-73 . Guan et al 6 retrospectively reviewed 1099 patients with COVID-19 and found that 35.8% of the patients had received oseltamivir therapy. The proportion of patients reaching the composite outcome (including ICU admission, need for mechanical ventilation and death) was higher in patients with oseltamivir administration than in those patients without oseltamivir therapy (9.2% vs 4.4%). This result could be interpreted by the fact that antiviral agents were more likely to be used in severe patients (46.2% vs 33.8% in non-severe) who tended to have a high viral load and a long virus-shedding period.

Currently, remdesivir appears to be the only antiviral agent with RCT evidence for shortening the time to recovery in COVID-19 patients. In an initial RCT in Wuhan, remdesivir use The recent results of the RECOVERY trial in the UK indicate that at the doses tested, the benefits of steroid treatment outweighed the potential harm. A total of 2,104 patients were randomized to receive 6 mg dexamethasone once per day for ten days and were compared with 4,321 patients randomized to usual care alone 81 14) . Therefore, the associations between corticosteroid use and disease severity and/or death that were found in observational studies might reflect a greater propensity to use corticosteroids in severe cases 1, 6, 79, 82, 83 . 

As of August 6, 2020, the case-fatality ratio of COVID-19 was 6.6% (4,512/68,138) in Hubei Mortality of COVID-19 associated AKI was mainly reported in studies from Wuhan 4, 8, 11, 19 . The pooled mortality was 77.2% (95%CI 51.9, 91.4) in patients with AKI vs. 9.0% (95%CI 3.6, 20.7)

in non-AKI COVID-19 total hospital admissions 4, 8, 11, 19 and the rate correlated with AKI severity stage (15.79% for AKI stage 1, 31.58% for AKI stage 2, and 52.63% in AKI stage 3, respectively) 4 . Given the lack of information, it is difficult to compare mortality rates among AKI patients requiring RRT in COVID-19 across studies. Nonetheless, extremely high mortality rate was observed in COVID-19 patients requiring RRT. Yang X et al. 7 

patients in their study and found that 8 out of 9 subjects who required CRRT did not survive.

In another study including 191 COVID-19 patients, 10 out of 10 subjects who required CRRT did not survive 2 .

Information on renal recovery in COVID-19-associated AKI is very limited. In Pei GC's study 4 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Kidney disease is associated with in-hospital death of patients with COVID-19

Renal Involvement and Early Prognosis in Patients with COVID-19

Prevalence of kidney injury and associations with critical illness and death in patients with COVID-19

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. American journal of respiratory and critical care medicine 2020

Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management. Beijing: People's Medical Publishing House

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Features and Short-term Outcomes of 102 Patients with

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Risk Factors Associated with Clinical Outcomes

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19

Clinical characteristics and risk factors of acute kidney injury in coronavirus disease

Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan

Distinct clinical characteristics and risk factors for mortality in female COVID-19 inpatients: a sex-stratified large-scale cohort study in Wuhan, China

Acute Kidney Injury in Patients with the Coronavirus Disease 2019: A Multicenter Study

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

AKI in Hospitalized Patients with and without COVID-19: A Comparison Study

Superior anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study

Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease 2019

Follow-Up of Multi-Organ Dysfunction and Inflammation Using Biomarker Kinetics in Patients with Severe COVID-19 Disease and Association with Disease Outcomes: Results from a Referral Center Cohort in the North East of France

Characteristics and outcomes of Acute Respiratory Distress Syndrome related to COVID-19 in Belgian and French Intensive Care Units according to antiviral strategies. The COVADIS multicenter observational study

Acute kidney injury in patients hospitalized with COVID-19

Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019

Acute kidney injury associated with coronavirus disease 2019 in Urban New Orleans

The Incidence, Risk Factors and Clinical Outcomes of Acute Kidney Injury in Critically Ill Patients with COVID-19: A Multicenter Study

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient

SARS-CoV-2 can be detected in urine, blood, anal swabs and oropharyngeal swabs specimens

Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan

Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan

Recommendations for prevention and control of novel coronavirus infection in blood purification center (room) from the Chinese Medical Association Nephrology Branch

Recommendation for prevention of COVID-19 virus infection in blood purification center

Covid-19 and Kidney Transplantation

Expert recommendation for postoperative follow-up and prevention and treatment of infection in organ transplanted recipients during the COVID-19 epidemic (trial version 1)

Strategies for Prevention and Control of the 2019 Novel Coronavirus Disease in the Department of Kidney Transplantation. Transplant international : official journal of the European Society for Organ Transplantation

Acute kidney injury in patients hospitalized with COVID-19

Fangcang shelter hospitals: a novel concept for responding to public health emergencies

China dispatches over 20,000 medics to aid anti-virus battle in Hubei. 2020

Reconstruction of the full transmission dynamics of COVID-19 in Wuhan

diagnosis and management of sepsis-induced acute kidney injury: a narrative review

Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of novel coronavirus cases in tertiary hospitals

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Effects of Corticosteroid Treatment for Non-Severe

Pneumonia: A Propensity Score-Based Analysis

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. The Journal of infection 2020

Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old

The diagnosis and treatment plan for the novel coronavirus disease(Tentative, the Seventh version)

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan

Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan

Traditional Chinese medicine for COVID-19 treatment

Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019-a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

How Does Continuous Renal Replacement Therapy Affect Septic Acute Kidney Injury?

Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study

Chinese Research Hospital Association Of Critical Care M, Youth Committee Of Chinese Research Hospital Association Of Critical Care M

Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19

Daily briefing on novel coronavirus cases in Hubei province. 2020